Blog
Clinical trials: increasing the visibility of research with visual abstracts
Communication of scientific results to the public is a very important part of research. The new EU CTR also requires that the results are communicated to the general public in a language understandable to lay persons. Furthermore, social media provides great dissemination channels for researchers to attract readers.
Das GKV-Finanzstabilisierungsgesetz und die Folgen für das AMNOG
Am 20. Oktober 2022 wurde das GKV-Finanzstabilisierungsgesetz (GKV-FinSt) mit den Stimmen der Ampel-Koalition verabschiedet. Mit dem Gesetz soll die Finanzierung der gesetzlichen Krankenversicherung für die Zukunft gesichert werden.
EU HTA Regulation: relevance, challenges and outlook
HTA stands for "Health Technology Assessment" and is used to systematically and transparently evaluate medical procedures and technologies from different perspectives. It aims to provide evidence-based information for physicians, health authorities, health insurers and patients.
Orphan Drugs in the process of the German Act on the Reform of the Market for Medicinal Products (AMNOG) – Quo Vadis?
The special position of Orphan Drugs in the process of the German Act on the Reform of the Market for Medicinal Products (AMNOG, Arzneimittelneuordnungsgesetz) is frequently criticized. In the following article, we will explain the concept of Orphan Drugs, elaborate their particular role and discuss the upcoming changes within the AMNOG process.
Artificial Intelligence (AI) in clinical research: transformation of clinical trials and status quo of regulations
Artificial Intelligence (AI) supported technologies play a crucial role in clinical research: For example, during the COVID-19 pandemic the Biotech Company BenevolentAI found through a machine-learning approach that the kinase inhibitor Baricitinib, commonly used to treat arthritis, could also improve COVID-19 outcomes.
EU CTR: How to write a good Lay Summary of clinical study results
Lay summaries are a display of clinical study results intended for study participants and the general public. The aim of a lay summary is not only to enhance understanding of complex medical information, but also to increase transparency in clinical research.